Fifth Circuit Deals Major Blow to DEA

The U.S. Court of Appeals for the Fifth Circuit delivered a significant setback to the Drug Enforcement Administration (DEA), vacating the agency’s order revoking a pharmacy’s certificate of registration. The ruling sharply rebukes the DEA for overstepping its authority and misapplying its own regulations — a development that could reshape how pharmacies defend themselves in enforcement actions.

At the heart of the case was the DEA’s claim that a Louisiana pharmacy failed to resolve “red flags” when dispensing certain controlled substances. But the Fifth Circuit found that the DEA did far more than apply existing law: it effectively rewrote its regulations while pretending to follow them. The court emphasized that federal agencies must apply the rules as written, not as they wish them to be.

One of the most consequential findings involved the DEA’s interpretation of the “corresponding responsibility” regulation, 21 C.F.R. § 1306.04(a). The DEA has long taken the position that a pharmacist violates this rule if they knew or had reason to know a prescription lacked a legitimate medical purpose. The Fifth Circuit rejected that standard outright, holding that the regulation requires actual knowledge that the prescription was invalid when issued. This dramatically narrows the circumstances under which the DEA can impose liability. The Fifth Circuit specifically held that 21 C.F.R. § 1306.04 “imposes liability on a pharmacist only if three conditions are met: the pharmacist (1) fills (2) an invalid prescription (3) knowingly.”  Neumann’s Pharmacy, L.L.C. v. Drug Enf’t Admin., 167 F.4th 320, 328 (5th Cir. 2026). The court further clarified that “[p]ut simply, a pharmacist violates § 1306.04(a) only by filling a prescription that was invalid when issued—that is, one written outside the prescribing physician’s usual course of professional practice.” Id. at 329.  

The court also rejected the DEA’s attempt to equate a pharmacist’s “usual course of professional practice” with a state-law standard of care which is another major limitation on the agency’s enforcement reach.

For years, the DEA has relied on broad, often subjective interpretations of “red flags” to justify aggressive enforcement actions. The Fifth Circuit’s ruling signals that courts will no longer rubber‑stamp those interpretations. Pharmacies now have stronger grounds to challenge DEA actions that stretch beyond the text of the Controlled Substances Act and its regulations.

While the case is being remanded, the message is unmistakable: the DEA must follow the law as written. And pharmacies facing similar scrutiny may now find themselves on far more even footing.

GWB represents pharmacies in DEA and DOJ investigations and related litigation. If you need support or would like to discuss your situation, please feel free to contact us.